Written questions by Jarvis.

What assessment he has made of the potential impact of increases in energy bills on consumers.

We recognise that bills going up will be worrying news for families. The reason for the increase to the price cap is due to an increase in wholesale energy costs which are influenced by international energy markets which we cannot control. This is why our Clean Power 2030 Mission is so vital. In the short term, we are extending support to ballplayers through the expanded Warm Home Discount, and we are working with Ofgem to accelerate work on a potential energy debt scheme.

Whether people receiving disability benefits for Ménière's disease will be exempt from her proposed reforms to the benefits system.

The Pathways to Work Green Paper set out a broad package of reforms to health and disability benefits and employment support. The functional impact and severity of a condition can significantly vary across individuals, so we are not planning for specific conditions to be exempt from the changes. Our reforms will ensure the most vulnerable and severely disabled people are protected, while supporting those who can work to do so. As such, the eligibility changes to PIP will not affect those who are unable to complete activities at all, and for new claimants on the Universal Credit health element after April 2026, we are proposing that those with the most severe, life-long health conditions will see their incomes protected.

What steps she is taking to help ensure all schools have the recommended allergy safeguards in place.

Section 100 of the Children and Families Act 2014 places a duty on maintained schools, academies and pupil referral units to make arrangements for supporting pupils with medical conditions. The accompanying statutory guidance makes clear to schools what is expected of them in taking reasonable steps to fulfil their legal obligations and to meet the individual needs of pupils with medical conditions, including allergies.

Innovation and Technology, whether he plans to introduce transparency obligations on generative AI developers to disclose information on creative works used in AI training.

The Government’s consultation on copyright and AI, which closed on 25 February, specifically sought views on a proposal to require AI model developers to be more transparent about how they obtain and use copyright works in their training.Our priority now is to review the evidence from the consultation which will inform the Government response, including any legislative proposals.

What assessment she has made of the potential impact of changes to visa rules for dependants of Master's students on international student recruitment.

There are many factors that influence international students when they choose to study abroad. These include the range and quality of available courses, the visa rules that apply in countries they are considering, and the appeal of living and studying in those countries.Several changes were made to the immigration system in 2024, restricting international students from bringing family members with them to the UK unless they are studying a PhD, doctorate or research-based higher degree. These restrictions will be continued, as confirmed by my right hon. Friend, the Secretary of State for the Home Department in early February, in line with the government’s commitment to manage migration carefully.This government has made clear its overall approach to international students. We will continue to welcome international students who enrich our university campuses, forge lifelong friendships with our domestic students and become global ambassadors for the UK.

What steps his Department is taking to support parents caring for children with long covid; and whether his Department plans to develop a long-term strategy to fund (a) biomedical research and (b) treatment for long covid in (i) adults and (ii) children.

The Government is committed to ensuring that families have the support that they need. The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, including support for carers, which can include parents.Across the National Health Service in England, there are services supporting people with post-COVID syndrome, often described as long COVID. These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. Further information can be found via the NHS website, at the following link:https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) remain committed to funding high-quality research to understand the causes, consequences, and treatment for long COVID. We are actively exploring next steps for research in this area.Between 2019/20 and 2023/24, through the NIHR and MRC, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.This includes funded clinical trials to test and compare different treatments such as antihistamines, anticoagulants, and anti-inflammatory medicines, as well as trials such as the approximately £1.5 million REGAIN trial funded through the NIHR. REGAIN is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID which combine exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.The approximately £1.9 million CLoCk study, co-funded by the NIHR and the MRC, developed an agreed definition of long COVID in children and young people as well as the associated symptoms, which will help harmonise research and improve understanding of the condition.Funding is available and we welcome funding applications for research into long COVID in both adults and children. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID. Further information about the society can be found at the following link:https://www.clinicalpcs.org.uk

What the average waiting time for driving tests is in Eastleigh constituency.

The table below shows the average waiting time in weeks for driving test centres that serve customers living in the Eastleigh constituency, as of 21 April 2025. Driving test centre (DTC)Average car practical driving test waiting time (21 April 25)Southampton (Maybush)24Winchester24 The current national average for driving tests as of March 2025 is 21.7 weeks.

Media and Sport, what assessment she has made of the potential implications for her policies of the reduction in VisitBritain's budget.

The GREAT Britain and Northern Ireland campaign has played and continues to play an important role in promoting the UK as a top global destination and supporting growth in the visitor economy. While decisions around the overall GREAT programme budget sit with the Cabinet Office, DCMS continues to work closely with the Minister for the Cabinet Office and other relevant departments to ensure that tourism remains a core focus of the campaign. Discussions are ongoing on how to maximise impact within available resources. We remain committed to working with VisitBritain and the wider sector to support the UK’s international tourism recovery, grow the visitor economy, and deliver on our ambition to attract 50 million inbound visitors by 2030.

What recent assessment he has made of trends in the level of maternity unit closures; and what steps he is taking to prevent the closure of maternity units.

There are real issues in maternity care, but also outstanding examples of care. It will not be an overnight recovery, but we will be making steady improvements to ensure all women receive safe, personalised, and compassionate care.The Government continues to work with the National Health Service as it delivers its three-year maternity and neonatal plan to improve maternity and neonatal services.The reconfiguration of services is a local decision that should be informed by clinical best practice, following appropriate engagement with patients and stakeholders. All service changes should be based on clear evidence that they will deliver better outcomes for patients.Responsibility for the delivery, implementation, and funding decisions for services ultimately rests with the appropriate NHS commissioner. Substantial planned service change should be subject to a full public consultation and should meet the Government and NHS England’s ‘tests’ to ensure good decision-making. The Government has not made an assessment of the closures to maternity services, as these are decisions best made locally.It is right that NHS services reflect changing demographics and birth rates, to ensure resources are used efficiently. At the same time, we expect maternity providers to listen to women and ensure they are given a choice at all stages of their pregnancy.

What assessment his Department has made of the potential side effects of the anti-malarial drug Lariam on civilian patients prescribed it in the UK.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses the available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions, including amending the product information.Mefloquine, commercially known as Lariam, is effective in the prevention and treatment of malaria, and is licensed for use by the MHRA in the United Kingdom. The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment, and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.Patient safety is our top priority, and no medicine would be approved unless it met our expected standards of safety, quality, and effectiveness. Our role is to continually monitor the safety of medicines during their use, including Larium. We have robust, safety monitoring and surveillance systems in place for all healthcare products.  When a safety issue is confirmed, we always act promptly to inform patients and healthcare professionals and take appropriate steps to mitigate any identified risk.

Whether his Department plans to review the (a) licensing and (b) prescribing guidelines for the anti-malarial drug Lariam.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses the available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions, including amending the product information.Mefloquine, commercially known as Lariam, is effective in the prevention and treatment of malaria and is licensed for use by the MHRA in the United Kingdom. The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.Patient safety is our top priority, and no medicine would be approved unless it met our expected standards of safety, quality, and effectiveness. Our role is to continually monitor the safety of medicines during their use, including Larium. We have robust, safety monitoring and surveillance systems in place for all healthcare products.  When a safety issue is confirmed, we always act promptly to inform patients and healthcare professionals and take appropriate steps to mitigate any identified risk.As with any medicine, clinicians are responsible for making prescribing decisions for their patients, taking into account best prescribing practice and the local commissioning decisions of their respective integrated care board.Clinicians are also expected to take account of appropriate national guidance on clinical effectiveness and safety, and are accountable for their prescribing decisions, both professionally and to their service commissioners. The national guidance for mefloquine is available at the following link:https://cks.nice.org.uk/topics/malaria-prophylaxis/prescribing-information/mefloquine/Prescribers are responsible for ensuring that any side effects experienced by their patients are addressed promptly, they should work with their patient to decide on the most suitable management plan, with the provision of the most clinically appropriate care for the individual always being the primary consideration.

What steps he is taking to ensure that integrated care boards provide gluten free bread prescriptions for patients with coeliac disease.

The Department has undertaken two national consultations in recent years on the prescribing of gluten-free foods in primary care. The rationale for this was the increased availability of these products in supermarkets and other food outlets at a time when the annual cost to the National Health Service of prescribing such items was £15.7 million. The first of these proposed changes to prescribing arrangements resulted in the Government’s decision to restrict such foods to bread and mixes.NHS England’s guidance, Prescribing Gluten-Free Foods in Primary Care, was developed to communicate to local commissioners, now integrated care boards (ICBs), the changes in legislation. Wording is included in the guidance which states that commissioners may further restrict the prescribing of gluten-free foods by selecting bread only, mixes only, or may choose to end the prescribing of gluten-free foods altogether, if they feel this is appropriate for their population, and whilst taking account of their legal duties to advance equality and have regard to reducing health inequalities. In NHS England’s guidance, there are no limits on the amount of bread or mixes that can be prescribed.Decisions about the commissioning and funding of local health services are the responsibility of local ICBs. NHS England’s guidance should be taken into account when ICBs formulate local policies, and prescribers are expected to reflect local policies in their prescribing practice. The guidance does not remove the clinical discretion of prescribers in accordance with their professional duties.

Whether he plans to increase the provision of pacemakers and implanted defibrillators.

The volume of implantable devices purchased by cardiac providers has increased by 22% in 2024/25, when compared with the same period in 2023/24. Commissioned providers determine the need for cardiac implantable electronic device (CIED) implantation using a multi-disciplinary team approach, which considers the needs of the individual patient and clinical guidelines.In 2023/24, approximately 60,000 CIEDs, which includes implantable cardioverter defibrillators and pacemakers, were implanted by National Health Service providers, as per the National Audit of Cardiac Rhythm Management report 2025.

Commonwealth and Development Affairs, what steps he is taking to monitor the safety and well-being of family members of individuals who worked with the UK Government in Afghanistan prior to Taliban rule.

We are continuing to support eligible Afghans who worked with us to resettle in UK. His Majesty's Government has welcomed over 31,000 eligible individuals, including family members, to the UK and continue to support relocation of the remaining eligible Afghans through our schemes.

Whether her Department has made an assessment of the potential impact of the proposed reforms to Personal Independence Payments on blind and partially sighted people.

Personal Independence Payment (PIP) is assessed on needs arising from a long-term health condition or disability rather than the health condition or disability itself. Individuals can be impacted by their health conditions in different ways and the assessment considers the effect on a person’s day to day life.Information on the impacts of the Pathways to Work Green Paper will be published in due course, and some information was published alongside the Spring Statement. These publications can be found in ‘Pathways to Work: Reforming Benefits and Support to Get Britain Working Green Paper’.A further programme of analysis to support development of the proposals in the Green Paper will be developed and undertaken in the coming months.

Whether the Trade Strategy will establish animal welfare standards that imports will be required to meet.

I refer the member for Eastleigh to the answer I provided to UIN 20696 on 20th December 2024.

What steps her Department is taking to reduce the administrative review backlog.

Caseworking resource for administrative reviews has doubled since 2021/22, which was the first of consecutive years of significantly increased demand. 2023/24 saw a 50% increase in AR applications compared to the previous year, and intake through 2024/25 continued at those same increased levels.The Home Office continues to work hard to meet the timescales set out in public guidance for the processing of administrative review applications.

What the average waiting time was for an administrative review of a visa decision between July 2024 and March 2025.

The information requested is not currently available from published statistics, and the relevant data could only be collated and verified for the purpose of answering this question at disproportionate cost. Current timescales for processing administrative review applications are set out at Ask for a visa administrative review: If you're in the UK - GOV.UK, which states: “Currently, it can take 12 months or more to receive the result of the administrative review. If you do not get a decision on your application within 6 months, the Home Office will contact you with an update.” For EUSS administrative review applications the current timescales are set out at: EU Settlement Scheme: administrative review - GOV.UK, which states: “We will continue to consider valid applications for an administrative review made before 4 April 2024. We have experienced unprecedented levels of applications which are causing a delay to our service. It can take 30 months or more to receive a result. If we have not made a decision within 6 months, we’ll contact you to update you on the situation”.

With reference to the National Audit Office report entitled Supporting people to work through jobcentres, published on 31 March 2025, what steps her Department plans to take to increase the number of jobcentre work coaches in the next 12 months; and whether she has made an assessment of the potential impact of the number of work coaches on jobcentres’ ability to provide the intended level of support.

We are reforming both the welfare and employment support systems to make best use of our work coaches’ time, ensuring a system that is fit for purpose. We are targeting support where it is needed most to tackle ill-health and disability-related economic inactivity. This includes £1 billion per year of new funding across the United Kingdom by the end of the decade to establish a new guarantee of support for all disabled people and people with health conditions claiming out of work benefits who want help to get into or return to work. We are also reforming our Jobcentres, bringing together Jobcentre Plus and the National Careers Service to meet the needs of local labour markets, people and employers whilst embracing technology to improve customer service and free up work coach time. Through reforming how we deliver our support, we can ensure people get the level of support they need and that we can get Britain Working. We will have further updates to this change programme in due course.

Food and Rural Affairs, whether he plans to provide bespoke protections for (a) the River Itchen and (b) other chalk streams; whether he plans to use planning reforms to support the protection of chalk streams; whether he plans to designate chalk streams and their surrounding habitats as irreplaceable; and what funding his Department plans to provide (i) for sustainable drainage systems in chalk catchments and (ii) to support higher water efficiency standards.

The River Itchen is already designated as a Special Area of Conservation and many of our chalk streams benefit from some form of designation. Chalk streams can be considered when setting the outcomes for a future system of environmental assessment. This Government is committed to securing better environmental outcomes alongside securing the development we need and is considering how best to reform environmental assessment processes with this objective in mind. This includes whether to take forward the powers in the Levelling-up and Regeneration Act to introduce Environmental Outcomes Reports Lastly, the National Planning Policy Framework recognises the role that well-designed SuDS schemes have in managing surface water while the National Framework for Water Resources sets out expectations for water efficiency including reducing leakage and long-term water usage.